Search | JOV | ARVO Journals

Showing 1 – 20 of 139

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Imaging in the Eye Conference Abstract July 2024

Measurement of Mitochondrial Dysfunction in Autosomal Dominant Optic Atrophy (ADOA) Assessed in FALCON, A Non-interventional, Natural History Study

Raghu Mudumbai; Joyce Liao; Patrick Yu-Wai-Man; Byron Lam; Marcela Votruba; Kelly Saluti; Yuw Wang; Barry Ticho; Steven Gross

Invest. Ophthalmol. Vis. Sci.. 2024; 65(9):PB00103.

ARVO Annual Meeting Abstract June 2024

Gildeuretinol Enables the Vitamin A Cycle

Hendrik P Scholl; Leonide Saad; Gabrielle DeBartolomeo; Neil M Bressler; Stephen H Tsang; Kimberly E Stepien; Paul S Bernstein; Byron L Lam; Michael B Gorin; Ilyas Washington; Christine Nichols Kay

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6438.

ARVO Annual Meeting Abstract June 2024

Exploring the Relationship Between Traumatic Brain Injury, Ocular Symptomatology, and Visual Photosensitivity

David Valdes; Heather Ann Durkee; Mariela C. Aguilar; Alex Gonzalez; Shivam Pinakin Patel; Cornelis Rowaan; Paula A. Sepulveda-Beltran; Gemayaret Alvarez; Barry E. Hurwitz; Byron L Lam; Elizabeth R. Felix; Jean-Marie A Parel; Anat Galor

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1825.

ARVO Annual Meeting Abstract June 2024

Impact of Light-Filtering Lenses on Visual Photosensitivity Threshold Reliability in Individuals with Traumatic Brain Injury

Heather Ann Durkee; Mariela C. Aguilar; Alex Gonzalez; David Valdes; Shivam Pinakin Patel; Cornelis Rowaan; Paula A. Sepulveda-Beltran; Gemayaret Alvarez; Barry E. Hurwitz; Byron L Lam; Elizabeth R. Felix; Anat Galor; Jean-Marie A Parel

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6358.

ARVO Annual Meeting Abstract June 2024

OCU400 Nuclear Hormone Receptor-Based Gene Modifier Therapy: Safety and Efficacy from Phase 1/2 Clinical Trial for Retinitis Pigmentosa Associated with NR2E3 and RHO Mutations

Byron L Lam; Arun K Upadhyay; Shankar Musunuri; Murthy Chavali; Sahar Matloob; Nalin Mehta; David G Birch; Paul Yang; Benjamin Bakall; Nieraj Jain; Jose S. Pulido; Borooah Shyamanga

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):406.

ARVO Annual Meeting Abstract June 2024

Longitudinal imaging of the parafoveal cone mosaic in congenital achromatopsia

Nickolas Chen; Katie M Litts; Danica Nikezic; Christopher S Langlo; Brian P Higgins; Byron L Lam; Fred Collison; Mark E Pennesi; Christine Nichols Kay; Sergey Tarima; Joseph Carroll

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1428.

ARVO Annual Meeting Abstract June 2024

Characterization of Retinal Mitochondrial Function and its Relations to Intraretinal Thicknesses and Capillary Perfusion Density in Older Healthy Adults

Hong Jiang; Ava-Gaye Y Simms; Byron L Lam; Collin Rich; Jianhua Wang

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3356.

ARVO Annual Meeting Abstract June 2024

Photoreceptor structure following gene therapy in CNGA3 -mediated Achromatopsia: adaptive optics imaging results from a Phase 1/2 dose escalation clinical trial for AGTC-402 (rAAV2tYF-PR1.7-hCNGA3)

Yu You Jiang; Peiluo Xu; Christine Nichols Kay; Robert Sisk; Rachel M Huckfeldt; Jason Comander; Byron L Lam; Ninel Z. Gregori; Audina Berrocal; Mark E Pennesi; Andreas K Lauer; Amy Christenson; Nadia K Waheed; Jessica Ijams Wolfing Morgan

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3289.

ARVO Annual Meeting Abstract June 2024

Mitochondrial Dysfunction in Autosomal Dominant Optic Atrophy (ADOA) Assessed in FALCON, A Non-interventional, Natural History Study

Raghu Mudumbai; Yaping Joyce Liao; Patrick Yu-Wai-Man; Byron L Lam; Marcela Votruba; Kelly Saluti; Yuw Wang; Steven Gross; Barry Ticho

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5268.

ARVO Annual Meeting Abstract June 2024

FALCON: A Prospective Natural History Study of Patients with Autosomal Dominant Optic Atrophy (ADOA)

Steven Gross; Yaping Joyce Liao; Patrick Yu-Wai-Man; Byron L Lam; Raghu Mudumbai; Marcela Votruba; Kelly Saluti; Yuw Wang; Barry Ticho

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5117.

Low Vision April 2024

Training in Cortically Blinded Fields Appears to Confer Patient-Specific Benefit Against Retinal Thinning

PDF

Berkeley K. Fahrenthold; Matthew R. Cavanaugh; Madhura Tamhankar; Byron L. Lam; Steven E. Feldon; Brent A. Johnson; Krystel R. Huxlin
TAGS: retinal thinning, training, visual training, retinal nerve fiber layer, cerebrovascular accident, ganglia
Invest. Ophthalmol. Vis. Sci.. 2024; 65(4):29. https://doi.org/10.1167/iovs.65.4.29

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2023

Worldwide multicenter ocular imaging study (EyeConic) to identify patients eligible for cone-based optogenetics therapy

Lucas Janeschitz-Kriegl; Zoltán Zsolt Nagy; Boris Rosin; Jacque L Duncan; Michel Michaelides; Byron L Lam; Samer Khateb; Katarina Stingl; Kaoru Fujinami; Giacomo Calzetti; Zi-Bing Jin; Karsten Borgwardt; Michael Adamer; Botond Roska; Bence Gyorgy; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5517.

ARVO Annual Meeting Abstract June 2023

MCO-010 intravitreal optogenetic therapy in Stargardt disease. 6-month outcomes from the Phase 2 STARLIGHT trial

Victor H Gonzalez; Byron L Lam; Vitaliy Zak; Samar Mohanty; subrata bataybal; Jean Chang; Ananta Ayyagari; Sai H Chavala; Jody Piltz-Seymour; John Koester; Aaron Osborne

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3546.

ARVO Annual Meeting Abstract June 2023

Assessment of Visual Photosensitivity with and without Light Filtering Lenses in Subjects with Traumatic Brain Injury

Shivam Patel; Mariela C Aguilar; Alex Gonzalez; Rhiya Mittal; Heather Ann Durkee; Paula Andrea Sepulveda Beltran; Gemayaret Alvarez; Barry E Hurwitz; Byron L Lam; Elizabeth Felix; Anat Galor; Jean-Marie Parel

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4236.

ARVO Annual Meeting Abstract June 2023

Leber Hereditary Optic Neuropathy Gene Therapy: Longitudinal Relationships Among Visual Function and Anatomical Measures

Byron L Lam; Vittorio Porciatti; Janet L Davis; D. Diane Zheng; Elizabeth Vanner; Eleonore J. Savatovsky; Diego Alba

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1957.

ARVO Annual Meeting Abstract June 2023

Twelve-month Natural History Study of CEP290- associated Retinal Degeneration

Bright Senyo Ashimatey; K. Thiran Jayasundera; Eric A Pierce; Carel C B Hoyng; Byron L Lam; Marc Dellacanonica; Keunpyo Kim; Rashid Rashid; Rene Myers; Mark E Pennesi

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3679.

ARVO Annual Meeting Abstract June 2023

Clinician Judged Visual Impairment and the Clinical Dementia Rating Scale Sum of Boxes in older adults

Dandan Diane Zheng; David Lee; Byron L Lam; Rosie Curiel; Elizabeth Crocco; David Loewenstein

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4218.

Vision Sciences Society Annual Meeting Abstract December 2022

Blind-field and intact-field training differentially impact retinal thinning after V1 damage

Berkeley Fahrenthold; Matthew Cavanaugh; Madhura Tamhankar; Byron Lam; Steven Feldon; Krystel Huxlin

Journal of Vision. 2022; 22(14):3708. https://doi.org/10.1167/jov.22.14.3708

ARVO Annual Meeting Abstract June 2022

Worldwide multicenter ocular imaging study (EyeConic) to identify patients eligible for cone-based optogenetics therapy

Lucas Janeschitz-Kriegl; Giacomo Calzetti; Michel Michaelides; Jose Alain Sahel; Zoltán Nagy; Katarina Stingl; Jin Zi-Bing; Jacque L Duncan; Eyal Banin; Byron L Lam; Michalis Georgiou; Boris Rosin; Viktória Szabo; Potyra Rosa; Bence György; Hendrik P Scholl

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):455.

ARVO Annual Meeting Abstract June 2022

Findings on visual photosensitivity in two phase 1/2 clinical trials of subretinal gene therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 achromatopsia

Rachel M Huckfeldt; Jason Comander; Mark E Pennesi; Paul Yang; Andreas Lauer; Robert Sisk; Edward Averbukh; Eyal Banin; Ninel Z Gregori; Janet L Davis; Byron L Lam; Christine Nichols Kay; Jessica Ijams Wolfing Morgan; Joseph Carroll; Bright Senyo Ashimatey; Matthew Feinsod

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):450.

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Measurement of Mitochondrial Dysfunction in Autosomal Dominant Optic Atrophy (ADOA) Assessed in FALCON, A Non-interventional, Natural History Study

Gildeuretinol Enables the Vitamin A Cycle

Exploring the Relationship Between Traumatic Brain Injury, Ocular Symptomatology, and Visual Photosensitivity

Impact of Light-Filtering Lenses on Visual Photosensitivity Threshold Reliability in Individuals with Traumatic Brain Injury

OCU400 Nuclear Hormone Receptor-Based Gene Modifier Therapy: Safety and Efficacy from Phase 1/2 Clinical Trial for Retinitis Pigmentosa Associated with NR2E3 and RHO Mutations

Longitudinal imaging of the parafoveal cone mosaic in congenital achromatopsia

Characterization of Retinal Mitochondrial Function and its Relations to Intraretinal Thicknesses and Capillary Perfusion Density in Older Healthy Adults

Photoreceptor structure following gene therapy in CNGA3 -mediated Achromatopsia: adaptive optics imaging results from a Phase 1/2 dose escalation clinical trial for AGTC-402 (rAAV2tYF-PR1.7-hCNGA3)

Mitochondrial Dysfunction in Autosomal Dominant Optic Atrophy (ADOA) Assessed in FALCON, A Non-interventional, Natural History Study

FALCON: A Prospective Natural History Study of Patients with Autosomal Dominant Optic Atrophy (ADOA)

Training in Cortically Blinded Fields Appears to Confer Patient-Specific Benefit Against Retinal Thinning

Worldwide multicenter ocular imaging study (EyeConic) to identify patients eligible for cone-based optogenetics therapy

MCO-010 intravitreal optogenetic therapy in Stargardt disease. 6-month outcomes from the Phase 2 STARLIGHT trial

Assessment of Visual Photosensitivity with and without Light Filtering Lenses in Subjects with Traumatic Brain Injury

Leber Hereditary Optic Neuropathy Gene Therapy: Longitudinal Relationships Among Visual Function and Anatomical Measures

Twelve-month Natural History Study of CEP290- associated Retinal Degeneration

Clinician Judged Visual Impairment and the Clinical Dementia Rating Scale Sum of Boxes in older adults

Blind-field and intact-field training differentially impact retinal thinning after V1 damage

Worldwide multicenter ocular imaging study (EyeConic) to identify patients eligible for cone-based optogenetics therapy

Findings on visual photosensitivity in two phase 1/2 clinical trials of subretinal gene therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 achromatopsia

To View More...

You must be signed into an individual account to use this feature.